Evaluation of See.d as an Automated Blood Sample Preparator for Multiple Liquid Biopsy Applications

Inclusion Criteria: * General (all participants) * Participants is willing and able to give and sign a written informed consent * Aged 18 or above * Specific for metastatic breast cancer patients * Female for metastatic breast cancer patients, aged 18 or above * Histological confirmation of breast cancer * Presence of at least one non-bone metastasis * Disease assessed to be in clinical or radiologic progression to the last line of treatment, as evaluated by the investigator * The biopsy, when recommended by the oncologist, is scheduled within 4 weeks after the date of blood withdrawal * Last biopsy or any other minor surgical procedure was perfomed at least 7 days before blood withdrawal * Known Bilirubin level ≥ 2 mg/dL on a blood sample collected within 7 days from the enrolment. If unavailable, it is not necessary to assess bilirubin * Specific for healthy participants * Both sexes for healthy volunteers, aged 18 or above * Healthy participants who visit the site for reason other than cancer diagnosis (including breast cancer). Exclusion Criteria: * Ongoing infections requiring antibiotic or antiviral treatment * Previous history of a blood cancer or an invasive non-BC apart from cancers treated with curative intent at least 3 years previously with no recurrence since diagnosis with the exception of non-melanoma skin cancer. For healthy participants also includes breast cancer * Undergone major surgery \< 4 weeks prior to the time of blood collection * Initiated a new line of treatment after disease progression at the time of blood or tissue biopsy collection * Presence of known severe coagulation or haematological disorder * Pregnancy * For metastatic breast cancer patients: histological confirmation of a Triple Negative Breast Cancer (TNBC)